<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Clinical Trial Insights</title>
  <style>
    body { font-family: Arial, sans-serif; padding: 2rem; background: #f5f6fa; }
    table { border-collapse: collapse; width: 100%; background: white; box-shadow: 0 2px 8px rgba(0,0,0,0.08); }
    th, td { padding: 0.6rem 0.9rem; text-align: left; border-bottom: 1px solid #e1e4eb; }
    th { background: #0f6db5; color: white; }
    tr:hover { background: #f0f8ff; }
  </style>
</head>
<body>
  <h1>Lab Demand Signals</h1>
  <table>
    <tr>
      <th>Principal investigator</th>
      <th>Email</th>
      <th>Product</th>
      <th>Demand signal</th>
      <th>Status</th>
      <th>Demand reason</th>
      <th>Trial</th>
      <th>Detected at</th>
    </tr>
    <tr><td>Pfizer</td><td></td><td>Adverse Event Grading Software</td><td>Medium</td><td>new</td><td>Used to grade adverse events and serious adverse events by type and severity.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Polysomnography Sensors</td><td>Medium</td><td>new</td><td>Required for comprehensive polysomnography to assess sleep parameters in participants.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Patient-Reported Outcome Questionnaires</td><td>Low</td><td>new</td><td>Used to assess patient-reported outcomes in global health status, symptoms, and quality of life.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Pain Inventory Questionnaires</td><td>Low</td><td>new</td><td>Used to assess patient-reported pain symptoms and time to deterioration.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>new</td><td>Comparator drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>RECIST 1.1 Imaging Analysis Software</td><td>Medium</td><td>new</td><td>Required for standardized assessment of tumor response and progression in trial participants.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Quality of Life (QoL) Questionnaires</td><td>Medium</td><td>new</td><td>Used to assess global health status, physical functioning, and role functioning in participants.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Quality of Life (QoL) Questionnaires</td><td>Medium</td><td>new</td><td>Used to assess kidney cancer symptom burden in participants.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>new</td><td>Study drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Drugs</td><td>High</td><td>new</td><td>Study drug administered orally once daily in combination with belzutifan.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>PARP Inhibitor Capsules</td><td>High</td><td>new</td><td>Used as the experimental drug in combination with enzalutamide for treatment of DDR-deficient mCSPC patients.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Placebo Capsules</td><td>High</td><td>new</td><td>Used as placebo control capsules identical in appearance to talazoparib for blinding in the control arm.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Androgen Receptor Inhibitor Capsules</td><td>High</td><td>new</td><td>Open-label androgen receptor inhibitor given daily to all participants in both arms.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Anti-Drug Antibody (ADA) Detection Kits</td><td>Medium</td><td>new</td><td>Needed to detect anti-drug antibodies against Lu AG13909 to monitor immunogenicity in participants.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Plasma Collection Tubes</td><td>High</td><td>new</td><td>Required for plasma collection for pharmacokinetic assessments of talazoparib, enzalutamide, and its metabolite.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Saliva Collection Devices</td><td>Low</td><td>new</td><td>Used for collection of late night salivary cortisol samples to assess LNSC endpoints.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Pharmacokinetic Sample Preparation Kits</td><td>Medium</td><td>new</td><td>Required for preparing plasma samples to measure pharmacokinetic parameters such as AUC, Cmax, Tmax, and clearance of Lu AG13909.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>cfDNA Extraction Kits</td><td>High</td><td>new</td><td>Used to extract circulating tumor DNA (ctDNA) from plasma samples for burden analysis.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Urine Drug Test Kits</td><td>High</td><td>new</td><td>Required for detecting substance abuse at multiple time points (Day 1, Day 4, Week 2, Week 4, Week 8) via urine drug screening.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Immunoassay Kits</td><td>Medium</td><td>new</td><td>Used to measure anti-HER3 antibody levels in plasma samples as part of pharmacokinetic assessments.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>new</td><td>Used for in vitro assays to support study of HER3-DXd efficacy and mechanism in RMS.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>new</td><td>Used for in vitro assays to support study of HER3-DXd efficacy and mechanism in hepatoblastoma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>LC-MS Reagents</td><td>High</td><td>new</td><td>Used for liquid chromatography-mass spectrometry analysis to quantify anti-HER3 antibody, anti-HER3-ac-DXd, and DXd in plasma samples.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Plasma Collection Tubes</td><td>High</td><td>new</td><td>Required for blood sample collection at specified intervals for pharmacokinetic analyses (AUC, Cmax, Ctrough) of anti-HER3 antibody, anti-HER3-ac-DXd, and DXd in plasma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>PSA Immunoassay Kits</td><td>Medium</td><td>new</td><td>Used to measure PSA levels for PSA response and progression endpoints.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Pfizer</td><td></td><td>Radiographic Imaging Contrast Agents</td><td>Medium</td><td>new</td><td>Required for radiological imaging to assess progression-free survival and objective response per RECIST 1.1.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:33:49</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>new</td><td>Used for in vitro studies to support efficacy and mechanistic investigations related to hepatoblastoma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Antibody-Drug Conjugates</td><td>High</td><td>existing</td><td>Study treatment administered via IV infusion to pediatric participants with relapsed or refractory solid tumors.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>PARP Inhibitor Capsules</td><td>High</td><td>new</td><td>Active drug used in experimental arm for treatment of DDR-deficient mCSPC patients.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>LC-MS Reagents</td><td>High</td><td>new</td><td>Required for liquid chromatography-mass spectrometry analysis to quantify anti-HER3 antibody, anti-HER3-ac-DXd, and DXd concentrations in plasma samples.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>Androgen Receptor Inhibitor Capsules</td><td>High</td><td>new</td><td>Open-label drug administered daily in both treatment arms.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>Placebo Capsules</td><td>High</td><td>new</td><td>Blinded placebo capsules used in control arm to match Talazoparib appearance.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>Plasma Collection Tubes</td><td>Medium</td><td>new</td><td>Required for plasma collection for pharmacokinetic assessments of talazoparib, enzalutamide, and metabolite levels.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>cfDNA Extraction Kits</td><td>Medium</td><td>new</td><td>Used for extraction of circulating tumor DNA (ctDNA) from plasma samples to assess ctDNA burden.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>RECIST 1.1 Imaging Contrast Agents</td><td>Medium</td><td>new</td><td>Used in radiological imaging to evaluate objective response and progression-free survival per RECIST 1.1 criteria.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>PSA Immunoassay Kits</td><td>Low</td><td>new</td><td>Used to measure PSA response and time to PSA progression in study participants.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Pfizer</td><td></td><td>Adverse Event Grading Software</td><td>Low</td><td>new</td><td>Software tool used to grade adverse events and serious adverse events by type and severity.</td><td>TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Saliva Collection Devices</td><td>Low</td><td>new</td><td>Required for collection of late night salivary cortisol samples to assess LNSC endpoints.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Pharmacokinetic Assay Kits</td><td>Medium</td><td>new</td><td>Used for measuring plasma concentrations of Lu AG13909 to determine pharmacokinetic parameters such as AUC, Cmax, Tmax, and half-life.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Urinary Free Cortisol (UFC) Assay Kits</td><td>High</td><td>existing</td><td>Used to quantify urinary free cortisol to evaluate UFC complete and partial response endpoints during titration and maintenance periods.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Anti-Drug Antibody (ADA) Detection Kits</td><td>Medium</td><td>new</td><td>Needed to detect anti-drug antibodies against Lu AG13909 to monitor immunogenicity during the trial.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>H. Lundbeck A/S</td><td></td><td>Cortisol ELISA Kits</td><td>High</td><td>existing</td><td>Required to measure cortisol levels in plasma and saliva samples to assess the effect of Lu AG13909 on cortisol in Cushing's disease patients.</td><td>A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Polysomnography Sensors</td><td>Medium</td><td>new</td><td>Required for comprehensive polysomnography to monitor sleep parameters in participants.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Urine Drug Test Kits</td><td>High</td><td>new</td><td>Required for detecting substance abuse at multiple time points (Day 1, Day 4, Week 2, Week 4, Week 8) to assess opioid and other drug use.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Questionnaire Forms</td><td>Low</td><td>existing</td><td>Self-reported questionnaire to assess nonmedical substance and alcohol use at multiple study visits.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Polysomnography Electrodes</td><td>Medium</td><td>existing</td><td>Used to measure total sleep time and wakefulness after persistent sleep onset in the sleep laboratory.</td><td>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Quality of Life (QoL) Assessment Kits</td><td>Medium</td><td>new</td><td>Cancer-specific QoL questionnaire to assess global health, physical and role functioning.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Inhibitors</td><td>High</td><td>new</td><td>Primary investigational drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Inhibitors</td><td>High</td><td>new</td><td>Co-investigational drug administered orally once daily in combination with belzutifan.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Oral Small Molecule Inhibitors</td><td>High</td><td>new</td><td>Comparator drug administered orally once daily to participants with advanced RCC.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>RECIST 1.1 Imaging Analysis Software</td><td>Medium</td><td>new</td><td>Used to assess tumor response and progression by RECIST 1.1 criteria in imaging studies.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Symptom Index Assessment Kits</td><td>Medium</td><td>new</td><td>Used to assess kidney cancer symptom burden and changes over time.</td><td>A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Plasma Collection Tubes</td><td>High</td><td>new</td><td>Used for blood sample collection at specified intervals for pharmacokinetic analyses (AUC, Cmax, Ctrough) of anti-HER3 antibody, anti-HER3-ac-DXd, and DXd in plasma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Immunoassay Kits</td><td>Medium</td><td>new</td><td>Used to measure anti-HER3 antibody levels in plasma samples as part of pharmacokinetic and safety assessments.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
    <tr><td>Merck Sharp & Dohme LLC</td><td></td><td>Cell Lines</td><td>Medium</td><td>new</td><td>Used for in vitro studies to support efficacy and mechanistic investigations related to rhabdomyosarcoma.</td><td>LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors</td><td>2025-12-23 02:31:56</td></tr>
  </table>
</body>
</html>
